Galectin-3 is a potential biomarker to insulin resistance and obesity in women with polycystic ovary syndrome

Alves, Michelle Teodoro; Souza, Isabella D P de; Ferreira, Cláudia N.; Cândido, Alexandre Luna; Bizzi, Mariana F; Oliveira, Flávio Roberto Azevedo de; Reis, Fernando M.; Gomes, Karina Braga

doi:10.1080/09513590.2020.1739267

Cited by 13 publications

(11 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The correlation of galectin 3 with BMI values has been demonstrated repeatedly in different study groups [30][31][32]. Our study con rmed this result.…”

Section: Discussionsupporting

confidence: 87%

“…Our study con rmed this result. Similar correlations with glucose and triglycerides have been previously described, and these relationships are especially often observed in women with polycystic ovary syndrome and pregnant women with preeclampsia [32,33]. These correlations were also described based on studies on cardiac patients [27] and with hypothyroidism [34].…”

Section: Discussionsupporting

confidence: 78%

“…It would seem that galectin 3 is a very interesting diagnostic tool, and many authors present it as a novel biomarker, np. Alves, Hrynchyshyn, Kanukurti, King [26,27,29,32]. However, doubts as to its diagnostic value are raised by the multitude of pathological conditions associated with an elevated level of this protein.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Glycation Markers in the Geriatrics Patients

Kuzan

Królewicz

Kustrzeba−Wójcicka

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Medical care for geriatric patients is a great challenge, mainly due to overlapping various deficits relevant to physiologic ageing with numerous coexisting diseases, of which the most common are diabetes mellitus and atherosclerosis. In case of diabetes, glycation process is intensified, which accelerates atherosclerosis development and diabetic complications. Our goal was to investigate the relationship between the classical biochemical parameters of diabetes and atherosclerosis (fasting glucose, glycated hemoglobin (HbA1c), low and high density lipoproteins (LDL, HDL), triglycerides, etc.), as well as parameters which may indicate a nephropathy (creatinine, glomerular filtration rate – GFR), and the parameters strictly related to glycation. Methods: We analyzed the patients' serum concentration of fluorescent glycation products, concentration of soluble receptor for advanced glycation products (sRAGE), lipoprotein receptor-1 (LOX-1), galectin 3 (GAL3), scavenger receptor class A (SR-A) and scavenger receptor class B (SR-BI), as well as the level of lipid peroxidation and free amine content. Results: Among the identified correlations, the most interesting are the following : sRAGE with triglycerides (r = 0.47); sRAGE with SR-BI (r=0.47); SR-BI with LOX-1 (r=0.31), and SR-BI with HDL (r=-0.30). It has been shown that pentosidine and fluorescent AGEs as well as reactive free amine contents are significantly higher in elderly patients with ischemic heart disease. Fluorescent AGEs and pentosidine are also significantly higher in patients with arterial hypertension. The influence of diabetes therapy on parameters related to peroxidation and glycation was also analyzed. Malondialdehyde turned to be higher in patients with diabetes mellitus type 2 not treated with insulin or metformin than in those treated with both medications (p=0.052). GAL3 was found to be lower both in persons without diabetes and in diabetics treated with metformin (p=0.005). LOX1 was higher in diabetic patients not treated with metformin or insulin, and lowest in diabetics treated with both insulin and metformin, with the effect of metformin reducing LOX1 levels (p=0.039). Conclusions: Our results were the basis for a discussion about the diagnostic value in clinial practice of LOX-1 and GAL3 in geriatric patients with diabetes and also provide grounds for inferring the therapeutic benefits of insulin and metformin treatment.

show abstract

“…The correlation of galectin 3 with BMI values has been demonstrated repeatedly in different study groups [30][31][32]. Our study con rmed this result.…”

Section: Discussionsupporting

confidence: 87%

Section: Discussionsupporting

confidence: 78%

See 1 more Smart Citation

Glycation Markers in the Geriatrics Patients

Kuzan

Królewicz

Kustrzeba−Wójcicka

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…In a high-fat diet induced IR mouse model study, silencing AnxA2 attenuated the obesity-induced insulin resistance and inflammation through the process of p50 nuclear translocation of the NF-κB signaling pathway [131]. Furthermore, AnxA2 interacts with galectin-3 at the cell surface, which directly induces cellular insulin resistance and associated inflammation under obese conditions by impairing insulin signaling [132][133][134]. As evidenced by recent studies, the anti-AnxA2 antibodies detected in severely infected COVID-19 patients suggest that AnxA2 expression is increased following SARS-CoV-2 infection, which could disrupt insulin signaling via the galectin-3 or NF-κB pathways, resulting in insulin resistance and hyperglycemia [42,135,136].…”

Section: Anxa2 Role In Insulin Resistancementioning

confidence: 99%

Molecular Insights on the Possible Role of Annexin A2 in COVID-19 Pathogenesis and Post-Infection Complications

Patil

Shetty

Kuriakose

et al. 2021

IJMS

View full text Add to dashboard Cite

Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) has infected >235 million people and killed over 4.8 million individuals worldwide. Although vaccines have been developed for prophylactic management, there are no clinically proven antivirals to treat the viral infection. Continuous efforts are being made all over the world to develop effective drugs but these are being delayed by periodic outbreak of mutated SARS-CoV-2 and a lack of knowledge of molecular mechanisms underlying viral pathogenesis and post-infection complications. In this regard, the involvement of Annexin A2 (AnxA2), a lipid-raft related phospholipid-binding protein, in SARS-CoV-2 attachment, internalization, and replication has been discussed. In addition to the evidence from published literature, we have performed in silico docking of viral spike glycoprotein and RNA-dependent RNA polymerase with human AnxA2 to find the molecular interactions. Overall, this review provides the molecular insights into a potential role of AnxA2 in the SARS-CoV-2 pathogenesis and post-infection complications, especially thrombosis, cytokine storm, and insulin resistance.

show abstract

“…Gal-3 has recently been recognized as an important modulator of biological functions and an emerging participant in the pathogenesis of immune/inflammatory and metabolic disorders[ 45 - 47 ] (Figure 1B ). Gal-3 serum levels are elevated in women with polycystic ovary syndrome, especially those with insulin resistance, and those with increased insulin and glucose levels in the glucose tolerance test and it is considered a potential biomarker in prediabetes and diabetes[ 48 - 50 ]. The role of Gal-3 in metabolic disorders and the mechanism by which this lectin modulates excess fat mass, adipose tissue, systemic inflammation, and the associated impairment of glucose regulation, remains to be elucidated.…”

Section: Gal-3 and Neuro-immuno-metabolic Crosstalkmentioning

confidence: 99%

Galectin-3 possible involvement in antipsychotic-induced metabolic changes of schizophrenia: A minireview

Borovcanin¹,

Vesić²,

Jovanović³

et al. 2021

WJD

View full text Add to dashboard Cite

Recently, specific immunometabolic profiles have been postulated in patients with schizophrenia, even before full-blown disease and independent of antipsychotic treatment. Proteomic profiling studies offer a promising potential for elucidating the cellular and molecular pathways that may be involved in the onset and progression of schizophrenia symptoms, and co-occurrent metabolic changes. In view of all this, we were intrigued to explore galectin-3 (Gal-3) as a glycan, and in our previous study, we measured its elevated levels in remission of schizophrenia. The finding may be a consequence of antipsychotic treatment and may have an impact on the onset of inflammation, the development of obesity, and the presumed cognitive changes in schizophrenia. In the animal study, it was shown that downregulation of Gal-3 was beneficial in insulin regulation of obesity and cognitive preservation. Strategies involving plasma exchange are discussed in this review, particularly in the context of Gal-3 elimination.

show abstract

Galectin-3 is a potential biomarker to insulin resistance and obesity in women with polycystic ovary syndrome

Cited by 13 publications

References 20 publications

Glycation Markers in the Geriatrics Patients

Glycation Markers in the Geriatrics Patients

Molecular Insights on the Possible Role of Annexin A2 in COVID-19 Pathogenesis and Post-Infection Complications

Galectin-3 possible involvement in antipsychotic-induced metabolic changes of schizophrenia: A minireview

Contact Info

Product

Resources

About